Press release
Abiomed Announces Second Quarter Fiscal 2014 Revenue of $44.3 Million, Up 19% Over Prior Year, Driven by Record Impella Utilization
DANVERS, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2014 revenue of $44.3 million, up 19% compared to revenue of $37.4 million in the same period of fiscal 2013, and a second quarter fiscal 2014 GAAP net income of $1.1 million or $0.03 per diluted share, compared to $5.5 million or $0.13 per diluted share in the prior year period.
Financial and operating highlights during the second quarter of fiscal 2014 and fiscal year to date include:
- Fiscal second quarter worldwide Impella® revenue totaled $40.2 million, up 23% compared to revenue of $32.8 million during the same period of the prior year. U.S. Impella revenue grew 21% to $37.0 million from $30.7 million in the prior year with U.S. Impella patient usage up 24% from the prior year.
- An additional 30 hospitals purchased Impella 2.5 during the quarter, bringing the total to 805 customer sites. As part of Abiomed's continued Impella CP™ launch, an additional 65 hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 237. Impella 2.5 and Impella CP unit inventory at hospitals averaged 2.4 units, equal to the prior sequential quarter.
- Gross margin rate for the second quarter of fiscal 2014 was 79.6% compared to 80.8% in the second quarter of fiscal 2013. There were 172 Impella AIC consoles placed during the quarter compared to 114 in the same period of the prior year.
- Income from operations for the second quarter fiscal 2014 was $1.4 million, compared to $5.9 million in the prior year period. Operating expense in the second quarter of fiscal 2014 included $1.9 million related to the Department of Justice subpoena and $0.7 million of medical device tax.
- Cash, cash equivalents, short and long-term marketable securities totaled $96.9 million as of September 31, 2013. The Company continues to have no debt and a U.S. federal net operating loss carry-forward of approximately $190 million as of March 31, 2013.
- Abiomed today announced that the Impella RP RECOVER RIGHT study has enrolled more than 50% of the required patients and as a result, HDE approval is forecasted for February 2015.
- In October, there were over 25 Impella-related sessions at the Transcatheter Cardiovascular Therapeutics (TCT) 2013 conference in San Francisco.
- In August, Abiomed received approval from the U.S. Department of Veterans Affairs to be included on its authorized Veteran's Administration (VA) Federal Supply Schedule, providing the Impella platform to VA medical facilities, Department of Defense (DOD) hospitals and other federal agencies.
"Abiomed achieved many new quarterly records on Impella utilization, including most overall patients, most prophylactic patients and most emergent patients," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "We are on track to transform into a PMA and PMDA company while setting new records in patient utilization and completing enrollment in our Impella RP study."
The Company is maintaining its fiscal year 2014 revenue guidance in the range of $180 million to $185 million, with worldwide Impella revenue forecasted to increase by approximately 20%, and GAAP operating margin of approximately breakeven to 5%.
The Company will host a conference call to discuss the results on Wednesday, November 6, 2013, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (877) 638-9567; the international number is (253) 237-1032. A replay of this conference call will be available beginning at 11 a.m. ET November 6, 2013 through 11:59 p.m. ET on November 13, 2013. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 86905153.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
| Abiomed, Inc. and Subsidiaries | ||
| Consolidated Balance Sheets | ||
| (Unaudited) | ||
| (in thousands, except share data) | ||
| September 30, 2013 | March 31, 2013 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $10,120 | $9,451 |
| Short-term marketable securities | 60,950 | 67,256 |
| Accounts receivable, net | 21,119 | 22,946 |
| Inventories | 15,636 | 14,930 |
| Prepaid expenses and other current assets | 2,789 | 2,022 |
| Total current assets | 110,614 | 116,605 |
| Long-term marketable securities | 25,811 | 11,406 |
| Property and equipment, net | 6,444 | 6,549 |
| Goodwill | 37,349 | 35,410 |
| Other assets | 801 | 29 |
| Total assets | $181,019 | $169,999 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,182 | $7,696 |
| Accrued expenses | 13,722 | 15,162 |
| Deferred revenue | 4,142 | 4,198 |
| Total current liabilities | 24,046 | 27,056 |
| Long-term deferred tax liability | 6,007 | 5,554 |
| Other long-term liabilities | 262 | 309 |
| Total liabilities | 30,315 | 32,919 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity: | ||
| Class B Preferred Stock, $.01 par value | -- | -- |
| Authorized - 1,000,000 shares; Issued and outstanding - none | ||
| Common stock, $.01 par value | 406 | 397 |
| Authorized - 100,000,000 shares; Issued - 40,659,164 shares at September 30, 2013 | ||
| and 39,788,383 shares at March 31, 2013; | ||
| Outstanding - 39,452,797 shares at September 30, 2013 | ||
| and 38,601,384 shares at March 31, 2013 | ||
| Additional paid in capital | 427,183 | 414,810 |
| Accumulated deficit | (258,925) | (258,261) |
| Treasury stock at cost - 1,206,367 shares at September 30, 2013 | ||
| and 1,186,999 shares at March 31, 2013 | (16,554) | (16,129) |
| Accumulated other comprehensive loss | (1,406) | (3,737) |
| Total stockholders' equity | 150,704 | 137,080 |
| Total liabilities and stockholders' equity | $181,019 | $169,999 |
| Abiomed, Inc. and Subsidiaries | ||||
| Consolidated Statements of Operations | ||||
| (Unaudited) | ||||
| (in thousands, except share data) | ||||
| Three Months Ended September 30, |
Six Months Ended September 30, |
|||
| 2013 | 2012 | 2013 | 2012 | |
| Revenue: | ||||
| Product revenue | $44,288 | $37,319 | $86,897 | $75,966 |
| Funded research and development | 57 | 98 | 118 | 234 |
| 44,345 | 37,417 | 87,015 | 76,200 | |
| Costs and expenses: | ||||
| Cost of product revenue | 9,027 | 7,194 | 17,750 | 14,640 |
| Research and development | 7,721 | 5,854 | 15,008 | 12,566 |
| Selling, general and administrative | 26,199 | 18,437 | 54,166 | 39,390 |
| Amortization of intangible assets | -- | -- | -- | 111 |
| 42,947 | 31,485 | 86,924 | 66,707 | |
| Income from operations | 1,398 | 5,932 | 91 | 9,493 |
| Other income (expense): | ||||
| Investment income (expense), net | 25 | 1 | 41 | (1) |
| Other income (expense), net | 6 | (9) | (15) | (13) |
| 31 | (8) | 26 | (14) | |
| Income before income tax provision | 1,429 | 5,924 | 117 | 9,479 |
| Income tax provision | 370 | 455 | 781 | 891 |
| Net income (loss) | $1,059 | $5,469 | $(664) | $8,588 |
| Basic net income (loss) per share | $0.03 | $0.14 | $(0.02) | $0.22 |
| Basic weighted average shares outstanding | 39,260 | 39,431 | 38,971 | 39,288 |
| Diluted net income (loss) per share | $0.03 | $0.13 | $(0.02) | $0.21 |
| Diluted weighted average shares outstanding | 41,337 | 41,722 | 38,971 | 41,645 |